title: The role of peptide YY in gastrointestinal diseases and disorders (review).
abstract: Peptide YY (PYY) is affected in several gastrointestinal diseases and disorders.             Changes in PYY appear to be an adaptive response to alterations in pathophysiological             conditions caused by the disease. This applies to gastrointestinal diseases/disorders             such as irritable bowel syndrome, inflammatory bowel disease, celiac disease,             systemic sclerosis, and post-intestinal resection. By contrast, the changes in             PYY in chronic idiopathic slow transit constipation (CST) seem to be of a primary             nature, and may be one etiological factor of the disease. Abnormalities in PYY             seem to contribute to the development of symptoms present in irritable bowel syndrome,             inflammatory bowel disease, gastroenteropathy in long-standing diabetes and CST.             The changes in PYY could, however, be favorable in some gastrointestinal disorders             such as celiac disease, systemic sclerosis and post-intestinal resection state.             Investigating changes in PYY in gastrointestinal diseases/disorders could be beneficial             in clinical practice, where a receptor agonist or an antagonist can be used as             a drug, depending on the condition. Similar to other neuroendocrine peptides/amines             of the gut, PYY has broad physiological/pharmacological effects: it can bind to             and activate several receptors with independent actions. Thus, in order to use             PYY as a drug, receptor-specific agonists or antagonists need to be developed.
authors.affiliation: Section for Gastroenterology, Department of Medicine, Stord Helse-Fonna Hospital, Stord, Norway. magdy.el-salhy@helse-fonna.no
authors.forename: Magdy
authors.initials: M
authors.lastname: El-Salhy
authors.forename: Tarek
authors.initials: T
authors.lastname: Mazzawi
authors.forename: Doris
authors.initials: D
authors.lastname: Gundersen
authors.forename: Jan Gunnar
authors.initials: JG
authors.lastname: Hatlebakk
authors.forename: Trygve
authors.initials: T
authors.lastname: Hausken
mesh_terms: D000818:Animals; D055808:Drug Discovery; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology* / Q000601:surgery; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology* / Q000601:surgery; D006801:Humans; D019894:Peptide YY / Q000032:analysis / Q000378:metabolism* / Q000627:therapeutic use
chemical_list: D005765:Gastrointestinal Agents; D019894:Peptide YY